Summary of Re-audit Follow-Up Results

Below is a summary of a follow-up on sustainability requirements for a supplier to Sweden's regions. The summary reflects the results of the audit as well as activities carried out as a result. It has been updated continuously as new activities related to the follow-up have been conducted, until all potential non-conformities have been addressed and the follow-up is considered complete.
For questions regarding the summary, please contact the Regional Office for Sustainable Procurement.

www.husr.se

Log

Last updated	2025-10-03

General Information

Supplier	Eli Lilly Sweden AB
Regions with Agreement	Västra Götalandsregionen (VGR)
Risk Area	Medicines
Product	ABASAGLAR 100 units/ml solution for injection in a cartridge ABASAGLAR 100 units/ml KwikPen solution for injection in a pre-filled pen
Type of Follow-Up	Digital Office Audit
Requirement	Sustainable supply chains & environmental requirements
Re-audit Date	2025-09-03
For more information	Jenny Forsell Skoog, jenny.forsell.skoog@vgregion.se Anders Lindberg, anders.e.lindberg@vgregion.se

Re-audit Results

Summary of the Re-audit	Eli Lilly Sweden AB demonstrated a strong cooperation and provided information effectively, both orally and through documentation, in accordance with the terms of the agreement and the action plan. Three out of five deviations were closed during the audit. However, deviations remain concerning the requirements for risk analysis and monitoring. Overall, Eli Lilly has made significant progress in complying with the contractual terms, and the auditors conclude that the company is on the right path toward full compliance.

Audit Results	**Sustainable Supply Chains**	**Assessment***
	1. Policy Commitment	**Compliant at re-audit, 2025-10-09**
	2. Forwarding of commitment	**Compliant at re-audit, 2025-10-09**
	3. Allocation of Responsibilities	Compliant at1st audit, 2024-10-09
	4. Risk Analysis	**Non-Conformance at re-audit 2025-10-09**
	5. Monitoring	**Non-Conformance at re-audit 2025-10-09**
	6. Non-Conformance Management	Compliant 1st audit, 2024-10-09
	Environmental Requirements	**Assessment ***
	1. Systematic environmental work	Compliant at 1st audit 2024-10-09
	2. Environmental policy	Compliant at 1st audit 2024-10-09
	3. Environmental investigation	Compliant at 1st audit, 2024-10-09
	4. Goals and action plans	Compliant at 1st audit, 2024-10-09

Explanations	
Non-Conformance	

	No identified non-conformities

*For a detailed description, see Appendix 1. Non-Conformities

Next Actions	Further follow – up/audit needed.

Appendix 1 - Non-Conformities

	Sustainable Supply Chains
Non-Conformity	Risk analysis. The supplier has initiated a Human Rights Risk Assessment and compiled data on its Swedish supply chain, but the methodology is incomplete. The analysis relies on a single, non-neutral source, lacks environmental risk coverage, and is limited to tier 1 suppliers. A comprehensive risk analysis and full supply chain mapping are not yet in place, meaning contractual requirements are not fulfilled.
Supplier's Action	Lilly will review the current Lilly Supply Chain Risk Methodology to better represent the contractual requirements. To update the current Lilly Supply Chain Risk Methodology, Lilly will use the Guidance documents found on the Sustainable Public Procurement website; Hållbar Upphandling). We will review/include reference to the Country Risks Table (this table takes a broader view of Country Risks than the one originally used by Lilly and is a compilation of the Worldwide Governance Indicators, the Global Rights Index*, the Environmental Performance Index and the Corruption Perception Index. All are given equal weight). As previously shared with the Auditors, Lillys risk analysis will cover the entire supply chain as per our original supplier contractual agreements (those contractual agreements were deemed satisfactory in the original reaudit process).
Timeline	December 31, 2025.
Non-Conformity	Monitoring. The supplier does not yet meet the requirements of clause 5 regarding monitoring. As a complete risk analysis is not yet in place, the supplier is unable to demonstrate how prioritized risks are systematically followed up in its own operations or in the supply chain.
Supplier's Action	Based on the risk analysis formed based on the actions in Deviation #1 Lilly will develop and execute systematic monitoring and follow up on the prioritised risks identified.
Timeline	April 1, 2026.